LASSEN THERAPEUTICS
Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The companyโs lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be more effective than targeting other factors such as TGF-ฮฒ and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.
LASSEN THERAPEUTICS
Industry:
Biotechnology Life Science
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.lassentherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(858) 251-7528
Email Addresses:
[email protected]
Total Funding:
31 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API WordPress Wordpress Plugins Nginx Sitelinks Search Box Microsoft Exchange Online
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Advisors List
Current Employees Featured
Founder
Investors List
Alta Partners
Alta Partners investment in Series A - Lassen Therapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Lassen Therapeutics
Longwood Fund
Longwood Fund investment in Series A - Lassen Therapeutics
Key Employee Changes
Date | New article |
---|---|
2021-11-18 | Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer |
Official Site Inspections
http://www.lassentherapeutics.com Semrush global rank: 8.08 M Semrush visits lastest month: 376
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Lassen Therapeutics" on Search Engine
Lassen Therapeutics - Crunchbase Company Profile & Funding
Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The companyโs lead candidate is LASN01, a monoclonal โฆSee details»
Lassen Therapeutics | LinkedIn
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases. site. http://www.lassentherapeutics.com. โฆSee details»
Lassen Therapeutics Presents New Data on LASN01 for the โฆ
Sep 11, 2023 Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease at the European Respiratory โฆSee details»
Lassen Therapeutics Launches to Discover and Develop Novel โฆ
Jun 17, 2020 SAN DIEGO-- ( BUSINESS WIRE )-- Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to โฆSee details»
Lassen Therapeutics Presents Phase I Data on LASN01, an IL-11 โฆ
SAN DIEGO, May 24, 2023--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R, โฆSee details»
Lassen Therapeutics Announces the Appointment of a Highly โฆ
Oct 7, 2021 SAN DIEGO-- ( BUSINESS WIRE )-- Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for โฆSee details»
Lassen Therapeutics Commences Dosing in Phase 1 Clinical โฆ
Sep 28, 2022 SAN DIEGO-- ( BUSINESS WIRE )-- Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for โฆSee details»
Lassen Therapeutics Launches with $31 Million to โฆ
Jun 18, 2020 Lassen Therapeutics has emerged from stealth and secured $31 million in series A financing to develop antibodies as potential treatments for fibrosis, rare diseases, and oncology. Frazier Healthcare โฆSee details»
Lassen Therapeutics Launches to Discover and Develop Novel โฆ
San Diego, CA, June 17, 2020 โ Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as โฆSee details»
Lassen Therapeutics Company Profile - Craft
Lassen Therapeutics is a company that develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. Its lead candidate is LASN01, a monoclonal โฆSee details»
Lassen Therapeutics Announces Closing of Oversubscribed $85 โฆ
SAN DIEGO, December 19, 2023 -- ( BUSINESS WIRE )-- Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics, LASN01, โฆSee details»
Lassen Therapeutics Launches to Discover and Develop Novel โฆ
Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, โฆSee details»
Lassen Therapeutics - Updates, News, Events, Signals & Triggers
Dec 21, 2023 News โข Jan 17, 2024. San Diego Business Journal โ Lassen Therapeutics Lands $85M Series B. News โข Dec 20, 2023. FinSMES โ Lassen Therapeutics Closes โฆSee details»
About - Lassen
© 2024 Lassen Therapeutics. Site Credits; LinkedInSee details»
Lassen Therapeutics - Funding, Financials, Valuation & Investors
Lassen Therapeutics has raised a total of. $116M. in funding over 2 rounds. Their latest funding was raised on Dec 19, 2023 from a Series B round. Lassen Therapeutics is โฆSee details»
Series B - Lassen Therapeutics - 2023-12-19 - Crunchbase
Dec 19, 2023 Organization Name. Lassen Therapeutics. Announced Date Dec 19, 2023. Closed On Date Dec 19, 2023. Funding Type Series B. Funding Stage Early Stage โฆSee details»
Lassen Therapeutics - Contacts, Employees, Board Members, โฆ
Lassen Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 6. Number of Board Member โฆSee details»
Our Science - Lassen
Contact. About . Our Approach. Leadership. Scientific Advisory Board. Pipeline. Our Science . IL-11. Careers. News. Contact. Our Science. © 2024 Lassen Therapeutics. Site โฆSee details»
Lassen Therapeutics - Tech Stack, Apps, Patents & Trademarks
Organization. Lassen Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Active Tech Count 11. โฆSee details»